



26th September 2019

GlaxoSmithKline Pakistan Limited
35-Dockyard Road,
West Wharf,
Karachi - 74000,
Pakistan

UAN +92 21 111 475 725
Fax +92 21 3231 4898
www.pk.gsk.com

The General Manager
Pakistan Stock Exchange
Stock Exchange Building
Stock Exchange Road
Karachi

Subject: **Material Information**

Dear Sir,

This is to inform shareholders that GSK has been contacted by regulatory authorities regarding the detection of genotoxic nitrosamine NDMA in ranitidine products and responding to their queries.

Based on the information received and correspondence with regulatory authorities, GSK made the decision to suspend the release, distribution and supply of all dose forms of ranitidine hydrochloride products to all markets, including Pakistan, as a precautionary action pending the outcome of ongoing tests and investigations.

GSK Pakistan has proactively informed the Drug Regulatory Authority of Pakistan (DRAP) about the above decision. Subsequently, the DRAP, vide notice dated 23rd September 2019, has advised Pharma Companies to recall all ranitidine-containing products in the market till further orders.

In order to comply with DRAP's instructions, GSK Pakistan is recalling all dose forms of Zantac from Distributors and Pharmacies.

GSK is continuing with investigations into the potential source of the NDMA. These investigations include continued engagement with our API suppliers. Patient safety remains our utmost priority and we are taking this issue very seriously.

Yours sincerely,

For and behalf of

Syed Azeem Naqvi
Company Secretary